NCT05012436View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics and Safety of YHD1119 in Subjects With Renal Impairment and Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 24, 2021

Primary Completion Date

May 10, 2022

Study Completion Date

May 10, 2022

Conditions
Healthy VolunteerRenal Impairments
Interventions
DRUG

YHD1119 75mg

A single oral dose

Trial Locations (2)

Unknown

CHA Bundang Medical Center, CHA University, Gyeonggi-do

The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul

All Listed Sponsors
lead

Yuhan Corporation

INDUSTRY

NCT05012436 - A Study to Evaluate the Pharmacokinetics and Safety of YHD1119 in Subjects With Renal Impairment and Healthy Subjects | Biotech Hunter | Biotech Hunter